Osteoporosis International

, Volume 1, Issue 1, pp 14–22

Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: Evidence that skeletal sensitivity is increased

  • M. A. Kotowicz
  • G. G. Klee
  • P. C. Kao
  • W. M. O'Fallon
  • S. F. Hodgson
  • S. L. Cedel
  • E. F. Eriksen
  • Daryl G. Gonchoroff
  • H. L. Judd
  • B. L. Riggs
Original Article

DOI: 10.1007/BF01880411

Cite this article as:
Kotowicz, M.A., Klee, G.G., Kao, P.C. et al. Osteoporosis Int (1990) 1: 14. doi:10.1007/BF01880411

Abstract

To define the role of parathyroid gland function in the pathophysiology of bone loss in type I (postmenopausal) osteoporosis, we measured serum intact parathyroid hormone (PTH) concentration by immunoradiometric assay (IRMA) and by multisite immunochemiluminometric assay (ICMA) in 63 postmenopausal osteoporotic women (PMOp) with vertebral compression fractures and in 75 age-comparable postmenopausal normal women (PMNl). Also, tetracycline-based histomorphometric indices in cancellous bone were assessed in iliac biopsy samples from 61 PMOp and 28 PMNl women. Serum PTH concentrations by IRMA were similar in PMOp and PMNl (medians, 3.92 and 3.77 pmol/l; NS) but were significantly lower in PMOp by the more sensitive ICMA (medians, 2.82 and 3.14 pmol/l;P<0.01). By multiple linear regression analysis, serum PTH was directly related (P<0.001) to activation frequency, bone resorption rate, bone formation rate, and the calculated rate of bone loss. For each unit (pmol/l) increase in serum PTH by ICMA, activation frequency increased by 1.3%/year more (P=0.01), bone resorption rate increased by 3.9%/year more (P=0.003), and the rate of cancellous bone loss was 2.8% greater (P= 0.0003) in the PMOp women compared with the PMNl women. Concentrations of serum estradiol, but not serum estrone, had a weak opposing effect to PTH, especially for bone formation rate. These data suggest that in PMOp the bone has increased sensitivity to the biologic effects of PTH. This may represent one of the fundamental pathophysiologic defects in PMOp and, in the setting of estrogen deficiency, may explain, in part, their greater rate of bone loss.

Keywords

Parathyroid hormone (PTH) Osteoporosis Bone resorption Bone formation 

Copyright information

© European Foundation for Osteoporosis 1990

Authors and Affiliations

  • M. A. Kotowicz
    • 1
  • G. G. Klee
    • 2
  • P. C. Kao
    • 2
  • W. M. O'Fallon
    • 3
  • S. F. Hodgson
    • 1
  • S. L. Cedel
    • 3
  • E. F. Eriksen
    • 1
  • Daryl G. Gonchoroff
    • 1
  • H. L. Judd
    • 4
  • B. L. Riggs
    • 1
  1. 1.Endocrine Research UnitMayo Clinic and Mayo FoundationRochester
  2. 2.Department of Laboratory Medicine and PathologyMayo Clinic and Mayo FoundationRochester
  3. 3.Department of Health Sciences ResearchMayo Clinic and Mayo FoundationRochester
  4. 4.Division of Reproductive EndocrinologyUniversity of California, Los AngelesLos Angeles

Personalised recommendations